Moshe Faynsod, M.D., F.A.C.S.
- Surgical Oncology
Other Languages Spoken
Moshe Faynsod, M.D., consistently earns rave reviews from patients impressed by his skills and bedside manner.
As a surgical oncologist with two decades' experience, Dr. Faynsod says he is “constantly striving to incorporate novel and emerging technologies to provide better and safer care for my patients.”
Dr. Faynsod received his medical degree at the University of Michigan, Ann Arbor, followed by residency at Harbor UCLA Medical Center. He also completed a surgical oncology fellowship here at City of Hope.
Dr. Faynsod is committed to the City of Hope mission of leading edge-care research combined with compassionate care. He treats patients at the City of Hope facility in Torrance, which holds a special appeal for him. “The opportunity to work with City of Hope, where I became a surgical oncologist and provide care in the community I’ve been a part of for over 20 years, is second to none,” he says.
- 2018-present, Assistant Clinical Professor, Division of Surgical Oncology, Department of Surgery, City of Hope South Bay, Torrance, CA
- 2007-2018, Staff Physician, General and Surgical Oncology Private Practice, San Pedro, CA
- 2017-2018, Vice Chief of Staff, Providence Little Company of Mary Medical Center San Pedro, San Pedro, CA
- 2004-2007, Associate Physician, North Shore Surgical Oncology Associates, Great Neck, NY
- 1991-1996, Doctor of Medicine, University of Michigan Medical School, Ann Arbor, Michigan
- 1987-1992, Bachelor of Science, Biochemistry, University of California Los Angeles, Los Angeles, CA
- 2002-2004, Surgical Oncology, City of Hope, Duarte, CA
- 2001-2002, Chief Resident, General Surgery, Harbor-UCLA Medical Center, UCLA School of Medicine, Los Angeles, CA
- 1996-2001, Resident, General Surgery, Harbor-UCLA Medical Center, UCLA School of Medicine, Los Angeles, CA
“A Case-Control Study of Laparoscopic Versus Open Sigmoid Colectomy for Diverticular Disease.” Southern California Chapter, American College of Surgeons. Huntington Beach, California. January 23, 2000.
“Patterns of Recurrence in Anal Canal Carcinoma.” 71st Annual Session of the Pacific Coast Surgical Association, San Francisco, California. February 22, 2000.
“CpG Oligonucleotides Enhance Potency of p53 Immunization in Rejecting Established Tumors.” Presented at the 57th Annual Cancer Symposium, Society of Surgical Oncology, New York, New York. March 18-22, 2004.
“Improved Hepatic Toxicity Profile of Adjuvant Hepatic Infusional Chemotherapy Utilizing the Portal Vein (PV) Route.” Presented at the 75th Annual Meeting of the Pacific Coast Surgical Association, Maui, Hawaii. February 15-17, 2004.
“CpG ODN Combined with MVAp53 Immunization Results in Rejection of Established Tumors in a Murine Model." Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, California. February 22-24, 2004.
“Is Routine Flexible Fiberoptic Bronchoscopy Justified Prior to Pulmonary Resection for Metastatic Disease?” Presented at the 58th Annual Cancer Symposium of the Society of Surgical Oncology. Atlanta, Georgia. March 3-6, 2005.
Faynsod M, Stamos M, Arnell T, Borden C, Udani S, Vargas H. A Case-Control Study of Laparoscopic Versus Open Sigmoid Colectomy for ! Diverticular Disease. The American Surgeon, 2000;66:841-843.
Faynsod M, Vargas H, Tolmos J, Udani V, Dave S, Arnell T, Stabile B, Stamos M. Patterns of Recurrence in Anal Canal Carcinoma. Archives of Surgery, 2000;135:1090-1095.
Lamont J, Faynsod M, Smith D, Pezner R, Ellenhorn J. Evaluation of Routine Radiation Boost Following Breast Conservation Therapy in Young Patients. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 709.
Faynsod M, Tolmos J, Karamatsu M, Ho J, Stamos M, de Virgilio C. Fibrin Glue Versus SeprafilmTM: A Comparison of Their Effect on Adhesions and Bowel Anastomosis. Submitted for Review, Journal of the American College of Surgeons.
Daftarian P, Ali S, Song G, Faynsod M, Longmate J, Diamond D, Ellenhorn J. Two Distinct Pathways of Immunomodulation Improve Potencey of p53 immunization in Rejecting Established Tumors. Cancer Research. 2004 Aug 1;64(15):5407-14.
Faynsod M, Wagman L, Carroll M, Leong L. Improved Hepatic Toxicity Profile of Adjuvant Hepatic Infusional Chemotherapy Utilizing the Portal Vein (PV) Route. City of Hope National Medical Center. J Clin Oncol 2005 23:4876-4880.
Faynsod M, Lamont J; Kakuda J; Leong, L; Wagman, L. Complications Related to Hepatic Regional Pump Therapy. City of Hope National Medical Center.
Faynsod M, Stamos MJ, Arnell T et al. (2000) A Case-Control Study of Laparoscopic versus OpenSigmoid Colectomy for Diverticulitis. Am Surg 66:841-843.
Faynsod M, Lamont J, Grannis F. Routine Bronchoscopy Prior to Pulmonary Metastectomy is Unlikely to Identify Occult Endobronchial Tumors. City of Hope National Medical Center. (Manuscript in Preparation)